Clinical Impact of Recurrence Beyond the Milan Criteria After Curative Resection of Hepatocellular, Takeshi Terashima, Hana Sanada, Noboru Takata, Tomoyuki Hayashi, Akihiro Seki, Hidetoshi Nakagawa Tadashi Toyama Shinichi Nakanuma, Isamu Makino, Kazuo Yasumoto, Shintaro Yagi, Taro Yamashita,, 00:1-11, 2025
Efficacy and safety of FOLFOX for Japanese patients with advanced biliary tract cancer as second-line or later chemotherapy (JON2107-Bstudy)., Terashima, Takeshi; Morizane, Chigusa; Chida, Akihiko; Todaka, Akiko; Umemoto, Kumiko; Kawakami, Yujiro; Yamashita, Tatsuya; Ueno, Makoto; Furuse, Junji; Nagano,, International Journal of Clinical Oncology, : , 2025
The efficacy and safety of adding hepatic arterial infusion chemotherapy using cisplatin to lenvatinib for advanced hepatocellular carcinoma., Terashima T, Yamamoto M, Toyama T, Kido H, Takata N, Hayashi T, Seki A, Nakagawa H, Nio K, Iida N, Yamada S, Shimakami T, Takatori H, Mizukoshi E, Honda M, Yamashita T, Hepatology Research, 55(7):1026-1037, Apr. 2025
A Multicenter Phase II Study on Atezolizumab plus Bevacizumab Combination Therapy in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh Classification B Cirrhosis: CHALLENGE Trial, Takeshi Terashima, Masafumi Ikeda, Taro Yamashita, Takuji Okusaka,
Hiroshi Imaoka, Tomokazu Kawaoka, Satoshi Kobayashi, Sadahisa Ogasawara, Atsushi Hiraoka, Masahito Nakano, Naohiro Okano, Rie Sugimoto, Michihisa Moriguchi, Yoshitaka Inaba, Satoru Shinoda, Makoto Ueno, Masatoshi Kudo, Junji Furuse,
Hiroaki Nagano,, : , Mar. 2026
